Bristol-Myers Squibb tops Q4 expectations, reports strong anemia drug sales
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Bristol Myers CEO sees mid-decade transition, late decade growth
February 2, 2024 7:04 AM ESTBy Michael Erman
(Reuters) -Bristol Myers Squibb's new chief executive said on Friday that the company was focused on driving growth toward the end of the decade but would first need to weather a difficult transition period beginning in 2026.
Bristol shares were up about half a percent in early trading.
Chris Boerner took over as CEO in November right after the company pared back expectations for its existing new product portfolio.
The company is expecting its top selling drugs, blood thinner Eliquis and cancer immunotherapy Opdivo, to lose patent protection later this decade. It... More
Bristol-Myers Squibb (BMY) Tops Q4 EPS by 10c, offers guidance
February 2, 2024 7:01 AM ESTBristol-Myers Squibb (NYSE: BMY) reported Q4 EPS of $1.70, $0.10 better than the analyst estimate of $1.60. Revenue for the quarter came in at $11.48 billion versus the consensus estimate of $11.22 billion.
GUIDANCE:
Bristol-Myers Squibb sees FY2024 EPS of $7.10-$7.40, versus the consensus of $7.39.... More
